Direct Healthcare Professional Communication on supply and safety concerns for CAELYX® (pegylated liposomal doxorubicin) 20 mg vials for injection

Janssen (Singapore) would like to update healthcare professionals on the CAELYX® supply shortages due to production difficulties at our specialty contract drug manufacturer's site, Ben Venue Laboratories (BVL), USA, following a potential risk of batch contamination due to the deficiencies in sterility assurance in quality management. The advisory to healthcare professionals include that existing CAELYX® stocks should only be used to complete treatment that has been initiated and no new patients should be initiated on CAELYX® treatment, until further notice. In addition, physicians may also wish to consider other treatment alternatives.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.